CASI vs ZLAB

For growth investors, Zai Lab Limited (ZLAB) is the stronger pick with 15.

3% revenue growth year-over-year, versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zai Lab Limited (ZLAB) delivered a total return of -86.

5%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: ZLAB returned -24. 8% versus CASI's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Zai Lab Limited's 1. 21β — meaning ZLAB is approximately -1088% more volatile than CASI relative to the S&P 500. On balance sheet safety, Zai Lab Limited (ZLAB) carries a lower debt/equity ratio of 31% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zai Lab Limited (ZLAB) is pulling ahead at 15.

3% versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zai Lab Limited (ZLAB) is the more profitable company, earning -38.

1% net margin versus -137. 6% for CASI Pharmaceuticals, Inc. — meaning it keeps -38. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZLAB leads at -49. 9% versus -138. 8% for CASI. At the gross margin level — before operating expenses — ZLAB leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CASI (31.

1% yield) pays a dividend. ZLAB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Both have compounded well over 10 years (CASI: -98. 9%, ZLAB: -24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CASI is a small-cap income-oriented stock; ZLAB is a small-cap high-growth stock. CASI pays a dividend while ZLAB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.